Overview Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma Status: Completed Trial end date: 2019-11-30 Target enrollment: Participant gender: Summary The study is to evaluate ORR, CR, PR DCR DOR PFS and safety of IBI308 in treatment of patients with Relapsed/Refractory Hodgkin's Lymphoma. Phase: Phase 2 Details Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.